Brief: Matinas Biopharma Holdings Inc Awarded Up To $3.75 Million From Cystic Fibrosis Foundation
20/11/2020 12:39
Nov 20 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA HOLDINGS INC - AWARDED UP TO $3.75
MILLION
FROM CYSTIC FIBROSIS FOUNDATION (CFF)
* MATINAS BIOPHARMA HOLDINGS INC - AWARD WILL SUPPORT
PRECLINICAL
DEVELOPMENT OF MAT2501
* MATINAS BIOPHARMA HOLDINGS INC - AWARD WILL SUPPORT
PRECLINICAL
IN VITRO & IN VIVO STUDIES, ALONG TOXICOLOGY STUDIES TO PROGRESS
MAT2501 INTO PHASE 2
Source text for Eikon: ID:nGNX844jZr
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing